Table of Contents
Introduction
While there have been significant developments in treating advanced urothelial cancer, it remains incurable and is a challenging condition. Although immunotherapy (cancer treatment), antibody-drug conjugates, and targeted medicines have demonstrated promising outcomes in many recent practice-changing trials, platinum-based chemotherapy remains the cornerstone of therapy for metastatic illness. So, if you have been diagnosed with urothelial cancer, know that there are several ways to treat it. However, the best option for you depends on factors like age, overall health, and cancer stage.
Surgical Options and Types of Surgery for Urothelial Cancer
1. Transurethral Resection of Bladder Tumor
In a transurethral resection of bladder tumor (TURBT), also known as transurethral resection (TUR), the physician removes any cancers from the bladder's inner lining and a small portion of the surrounding muscle. A resectoscope, a narrow, rigid cystoscope, is inserted into your bladder through the urethra. The wire loop at the end of the resectoscope removes tumors or aberrant tissues; it also features a tiny telescope the doctor can see through. Usually, after the TURBT, the medicine is injected into the bladder to try to eradicate any cancer cells that may still be there. We refer to this as intravesical treatment.
2. Partial Cystectomy
If the cancer has spread into the bladder's muscle layer (muscle-invasive bladder cancer or MIBC) or if there is a high risk of it, the doctor might recommend a cystectomy. It may occasionally be possible to remove the cancer along with a portion of the bladder wall without removing the entire bladder if it has only spread to a single, small area of the muscular layer of the bladder wall. Stitches are then used to seal the bladder wall hole. To check for cancer spread, nearby lymph nodes are also removed.
3. Radical Cystectomy
The best course of action is frequently a radical cystectomy if the malignancy is larger or spreads to multiple bladder areas. During this procedure, the bladder and any surrounding lymph nodes are removed. Seminal vesicles and the prostate are also removed in men. The ovaries, uterus (womb), cervix, fallopian tubes (tubes connecting the ovaries and uterus), and a tiny portion of the vagina are also removed from women.
Nonsurgical Treatment for Urothelial Cancer
1. Chemotherapy for Urothelial Cancer
Sometimes, doctors may recommend chemotherapy before surgery. This is 'neoadjuvant therapy', which mainly aims to shrink the tumor. It makes it easier to remove and also probably reduces the chance of cancer relapse. Neoadjuvant therapy refers to the administration of chemotherapy before surgery. Adjuvant therapy aims to eradicate any cancer cells that could still be present following prior therapies. This can reduce the likelihood of the cancer returning in the future. This treatment also uses intravenous chemotherapy, in which the chemotherapy medication is administered directly into the bladder. The most common usage of this kind of chemotherapy is for bladder cancer that has not spread far into the bladder lining.
2. Radiation Therapy for Urothelial Cancer
External beam radiation therapy is the most commonly utilized form of radiation to treat bladder cancer. It directs radiation at the cancer from an external source. Some bladder cancers that are detected early can be treated with radiation therapy following surgery that does not remove the entire bladder. To help prevent or treat symptoms of advanced bladder cancer, as part of the treatment for patients who are unable to have a cystectomy (a surgery to remove the bladder) or as part of the treatment for advanced bladder cancer (cancer that has spread beyond the bladder). To make the radiation operate better with fewer side effects, radiation therapy is frequently administered in conjunction with chemotherapy (with medications like Cisplatin, Gemcitabine, Capecitabine, or 5-FU + Mitomycin). We call this chemoradiation.
3. Immunotherapy for Urothelial Cancer:
A wide range of immunotherapy treatments is available that can help fight different cancers. Each type works in its unique way and helps to boost your body's natural defense mechanism.
Types of cancer immunotherapy encompass:
1. Checkpoint Inhibitor Therapy
One kind of cancer immunotherapy is checkpoint inhibitor therapy. The treatment prevents immune checkpoint proteins, important immune system regulators, from attaching to other proteins. This stops the signal from being sent and, consequently, the immune cells (T-cells) from following the attack on foreign cancer cells. When chemotherapy or surgery fails to treat advanced stages of cancer, this therapy works well.
2. Chimeric Antigen Receptor (CAR) T-cell Therapy
One of the adoptive cell therapies that increases the immune system's capacity to eliminate malignant cells is chimeric antigen receptor (CAR) T-cell therapy. When taking this medicine, T lymphocytes, or T cells, are more effective as cancer-fighting machines. Large numbers of CAR-T cells are created in a lab and reintroduced into the patient's body to eradicate cancerous cells. This is beneficial in treating blood cancer.
3. Tumour-Infiltrating Lymphocytes
Tumor-infiltrating lymphocytes are immune cells that can identify and eliminate cancerous cells. They are extracted from a patient's tumor, cultivated in labs in vast quantities, and then returned to the patient as part of cancer therapy to aid the immune system in more efficiently eliminating the cancerous cells. The FDA (Food and Drug Administration) has approved this medicine as a routine immunotherapy treatment for cancer.
4. Immune Checkpoint Inhibitor
Immune cells, such as T cells and certain cancer cells, manufacture checkpoint proteins that are blocked by immune checkpoint inhibitor antibodies. As a result, the checkpoint proteins become inactive, allowing T lymphocytes to more easily destroy cancer cells.
Targeted Therapies:
What Are Targeted Therapies?
Targeted therapy is a type of cancer treatment that specifically targets and destroys particular cancer cell types using medications or other chemicals. It may be utilized alone or in conjunction with other therapies, such as radiation therapy, surgery, or conventional or standard chemotherapy.
How Targeted Therapy Works in Urothelial Cancer?
Targeted therapies can identify and stop specific instructions delivered inside a cancer cell that instruct it to proliferate, or they can locate and target particular regions or materials within cancer cells.
The following are some of the compounds found in cancer cells that are "targets" of targeted therapies:
-
A cancer cell with an excess of a certain protein.
-
A protein that is absent from healthy cells but present in cancer cells.
-
A protein on a cancer cell that has undergone some sort of mutation.
-
DNA (gene) alterations that are not present in healthy cells.
Targeted medications can act in the following ways:
-
Stop or disable the chemical cues that cause the cancer cell to proliferate and divide.
-
Alter the proteins in the cancer cells to cause them to die; cease the development of new blood vessels to provide the cancer cells with nutrients.
-
Make your immune system work to eradicate the cancerous cells.
-
Deliver poisons to cancer cells to destroy them, but not healthy cells.
-
Their action can influence where these medications work and what side effects they produce.
-
It is crucial to remember that some targeted therapy medications, such as monoclonal antibodies, have many mechanisms of action to suppress cancer cells. Because they strengthen the immune system, they may also be categorized as immunotherapy.
Latest Targeted Therapy Options
1. Inhibitor of FGFR
Bladder cancer cells have a set of proteins called fibroblast growth factor receptors (FGFRs) that can aid in their proliferation. The FGFR genes, which regulate the amount of FGFR proteins produced, are altered in the cells of various bladder tumors. Some patients with bladder cancer may benefit from treatment with FGFR inhibitors, medications that target cells with FGFR gene mutations.
2. Antibody-Drug Conjugates
Targeted therapy could include antibody-drug conjugates (ADCs). These medications comprise a monoclonal antibody, a laboratory-produced form of an immune system protein that binds to a particular target on cancer cells, and a chemotherapy agent. Once within the body, the ADC's antibody component is a homing device, delivering the chemotherapy straight to the cancerous cells. ADCs such as Enfortumab Vedotin can be used to treat bladder cancer.
Conclusion
The primary basis for bladder cancer treatment is the cancer's clinical stage at the time of initial diagnosis. This is your doctor's best assessment of the cancer's growth, based on the examinations and tests performed thus far. The stage considers the extent to which the cancer is believed to have penetrated the bladder wall and whether it has spread outside of the bladder. In particular, non-muscle invasive bladder cancers (NMIBCs), which are early-stage cancers that have not yet spread to the muscle layer of the bladder wall, depend on other factors like the size of the tumor, the rate at which the cancer cells are growing (the grade of the cancer), and the number of tumors. These variables can be used to establish the cancer's risk category, which may then influence available treatments.
Keynotes:
The urothelium tissue that lines your bladder, kidneys, and other urinary system components is where urothelial carcinoma begins. Combination chemotherapy (the use of two or more drugs to treat cancer) can offer both palliation and a moderate chance of survival for urothelial tumors, which are chemosensitive. For more information or to consult a specialist, visit iCliniq.
